Peginterferon alfa-2a
- Generic Name
- Peginterferon alfa-2a
- Brand Names
- Pegasys
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 198153-51-4
- Unique Ingredient Identifier
- Q46947FE7K
- Background
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, HBeAg Positive Chronic Hepatitis B
- Associated Therapies
- -
Cemiplimab/Peg-Interferon-α in Advanced CSCC
- Conditions
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Baptist Health South Florida
- Registration Number
- NCT05729139
- Locations
- 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2019-05-22
- Target Recruit Count
- 100
- Registration Number
- NCT03920605
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2019-04-19
- Target Recruit Count
- 120
- Registration Number
- NCT03919565
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Target Recruit Count
- 150
- Registration Number
- NCT03480932
- Locations
- 🇮🇳
YR Gaitonde Centre for AIDS Education and Johns Hopkins University Collaborative Integrated Care Center (YRG-JHU ICC), Bilaspur, Chhattisgarh, India
Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 73
- Registration Number
- NCT03272009
- Locations
- 🇦🇺
Scientia Clinical Research Limited, Sydney, New South Wales, Australia
🇳🇱Academic Medical Centre (AMC), Amsterdam, Netherlands
🇳🇱Erasmus MC, Rotterdam, Netherlands
The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection
- Conditions
- Interventions
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 432
- Registration Number
- NCT03253250
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, China
The Changes of Treg Cells Frequency and Function During Antiviral Therapy
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03210493
- Locations
- 🇨🇳
Beijing Ditan hospital,Capital Medical University, Beijing, Beijing, China
The Changes of Cytokines During Antiviral Therapy
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03210506
- Locations
- 🇨🇳
Beijing Ditan hospital,Capital Medical University, Beijing, Beijing, China
The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Yao Xie
- Target Recruit Count
- 100
- Registration Number
- NCT03209011
- Locations
- 🇨🇳
Beijing Ditan hospital,Capital Medical University, Beijing, Beijing, China
The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03209037
- Locations
- 🇨🇳
Beijing Ditan hospital,Capital Medical University, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.